Living with kidney cancer, known as renal cell carcinoma, brings many unknowns about how the disease will progress. Doctors are looking for better ways to predict how a patient might fare. A recent look at data from 587 patients suggests that a specific calculation called the CALLY index could offer more clarity. This index combines three different markers in the blood: C-reactive protein, albumin, and lymphocytes.
The analysis found that patients with a low CALLY index had a higher risk of their cancer progressing and a lower chance of overall survival. Specifically, a low score was linked to a much higher risk of the disease worsening. While this tool shows promise as a way to help predict outcomes, it is important to note that the data comes from several older studies rather than a single new clinical trial.
Because the patients in these studies were very different from one another, the results are not yet certain enough to say exactly how it affects specific stages of cancer or specific treatments. It is currently seen as a helpful extra piece of information for doctors to consider, rather than a definitive rule. Patients should talk with their oncology team to see how these markers might apply to their specific situation.
